Welcome to our dedicated page for Omnicell news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell stock.
Omnicell, Inc. (NASDAQ: OMCL) develops healthcare technology for autonomous medication management across pharmacy and nursing care settings. Its updates cover financial results, product bookings, recurring revenue, connected-device demand, and product launches such as Omnicell Titan XT and the OmniSphere platform.
Company news also includes healthcare conference presentations, customer engagement programs, clinical leadership roles, and innovation updates tied to automation, AI-enabled intelligence, software workflows, data analytics, and expert services for medication management in healthcare facilities.
Omnicell, a leader in medication management, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 8:15 a.m. Pacific Time. The presentation will be available via live and archived webcasts on Omnicell's website. Established in 1992, Omnicell focuses on enhancing pharmacy care delivery through automation and technology, aiming to improve patient safety and operational efficiency for healthcare providers. Their innovative solutions help reduce medication errors and hospital readmissions across North America and the UK.
Omnicell is set to showcase its Advanced Services at the ASHP Midyear Clinical Meeting from December 5-8, 2022, in Las Vegas. These services include IV Compounding, Central Pharmacy Dispensing, Inventory Optimization, Retail Pharmacy, and Specialty Pharmacy Services, all aimed at enhancing medication management efficiency and patient safety. The company's strategy focuses on integrating technology to improve clinical outcomes and create economic value for health systems. Omnicell's efforts could potentially lead to improved operational efficiency and reduced medication errors across healthcare settings.
Omnicell, Inc. (Nasdaq:OMCL), a prominent provider of medication management solutions, will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 9:00 a.m. ET. The presentation will feature Randall Lipps, Chairman, President, and CEO, alongside CFO Peter Kuipers. Interested parties can access live and archived webcasts on the Omnicell website. Omnicell has been dedicated to improving pharmacy care delivery since 1992, focusing on enhancing patient safety and operational efficiency through innovative technologies.
Omnicell reported third-quarter 2022 revenues of $348 million, reflecting a 17% increase year-over-year, yet faced profit declines. GAAP net income dropped to $17 million ($0.37 per diluted share), down from $29 million ($0.61) in Q3 2021. Non-GAAP net income was $45 million ($1.00 per diluted share), down from $50 million ($1.08). The company lowered its 2022 guidance amid capital budget freezes, expecting total revenues between $1.284 billion to $1.294 billion. Despite near-term challenges, Omnicell remains confident in its long-term strategy.
Omnicell, Inc. (Nasdaq:OMCL) will announce its Q2 2022 financial results on November 2, 2022, before the market opens. Following the announcement, a conference call and webcast are scheduled for 8:30 a.m. ET. The event will be accessible to the public via phone and through Omnicell’s Investor Relations website.
Founded in 1992, Omnicell focuses on enhancing medication management and adherence in healthcare, aiming to reduce costs and improve outcomes with its technology-driven services.
Omnicell, Inc. has launched its Specialty Pharmacy Services, a new solution aimed at enhancing medication management for health systems and pharmacies. This initiative addresses the projected $316 billion specialty drug market by 2025, focusing on improving patient care and financial outcomes through a comprehensive service model. The offering aims to help hospitals establish and optimize specialty pharmacy operations, enhancing access to medications and driving revenue. With the rapid rise of chronic illnesses, Omnicell's services are timely in addressing healthcare demands.
Omnicell, Inc. (NASDAQ: OMCL) held its 2022 Investor Day, highlighting its transformation to an Advanced Services business model aimed at achieving long-term growth. The company anticipates this model will represent 20% to 30% of total revenue by 2025, targeting $1.9 billion to $2.0 billion in revenue with a 14% to 15% CAGR. Omnicell boasts a $90 billion+ total addressable market and partnerships with major health systems. The event reaffirmed its focus on ESG strategies and disciplined execution for sustainable, profitable growth.
Omnicell, Inc. (Nasdaq:OMCL), a leader in medication management solutions, announced participation in the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 1:55 p.m. ET. Scott Seidelmann, Executive VP and Chief Commercial Officer, will present.
Webcasts will be available live and archived on Omnicell's website. Founded in 1992, Omnicell aims to enhance pharmacy care delivery through automation and technology, impacting facilities across North America, the UK, Germany, and Australia. For more information, visit www.omnicell.com.
Omnicell will host an Investor Day on September 20, 2022, at 1:00 p.m. Eastern Time. The event will feature presentations from the executive leadership team discussing the company’s unique business strategy and long-term financial outlook, followed by a Q&A session. Speakers include CEO Randall Lipps, CFO Peter Kuipers, CCO Scott Seidelmann, and SVP Danny Sanchez. A live webcast will be available on Omnicell's website, and a replay will follow the event.
Omnicell, listed on NASDAQ under the symbol OMCL, focuses on enhancing medication management to improve patient outcomes.
Omnicell, Inc. (NASDAQ:OMCL) reported Q2 2022 GAAP revenues of $331 million, a 22% increase year-over-year, despite a modest impact from a ransomware incident. GAAP net income was $9 million or $0.20 per diluted share, down from $20 million or $0.43 a year ago. Non-GAAP revenues also rose to $332 million, with non-GAAP net income at $38 million or $0.84 per diluted share, compared to $44 million or $0.97 previously. The company reaffirmed its full-year guidance, expecting revenues between $1.385 billion and $1.410 billion.